Overview
Diabetic retinopathy is a diabetes-related complication that affects the retina, the light-sensitive tissue at the back of the eye. It results from chronic high blood sugar levels damaging the small blood vessels in the retina, leading to leakage, swelling, and the growth of abnormal new vessels. If left untreated, it can progress to vision impairment and blindness. Diabetic retinopathy is a leading cause of preventable blindness among working-age adults worldwide, and its prevalence correlates with the duration and control of diabetes.
1.1 Microvascular Damage
1.1.1 Pericyte Loss and Capillary Basement Membrane Thickening
Chronic hyperglycemia induces the selective loss of retinal capillary pericytes, contractile cells that maintain vascular stability. Concurrently, the capillary basement membrane thickens due to the accumulation of extracellular matrix components such as collagen and fibronectin. These structural changes weaken the vessel wall, predisposing capillaries to microaneurysm formation and leakage.
1.1.2 Endothelial Dysfunction and Blood-Retinal Barrier Breakdown
Hyperglycemia impairs the function of retinal endothelial cells, reducing tight junction protein expression (e.g., occludin, claudin-5). This compromise of the inner blood-retinal barrier allows plasma components (e.g., lipids, proteins) to extravasate into the retinal interstitium, contributing to edema and hard exudate deposition.
1.2 Ischemia and Neovascularization
1.2.1 Vascular Endothelial Growth Factor (VEGF) Upregulation
Retinal ischemia triggers hypoxia-inducible factor (HIF)-1α stabilization, which upregulates VEGF expression in retinal cells (e.g., Müller cells, retinal pigment epithelium). Elevated VEGF levels promote vascular permeability and endothelial proliferation.
1.2.2 Retinal Angiogenesis and Vitreous Hemorrhage
VEGF-driven neovascularization produces fragile, leaky blood vessels that grow along the inner retinal surface and into the vitreous cavity. These abnormal vessels are prone to rupture, causing vitreous hemorrhage. Subsequent fibrovascular proliferation can lead to tractional retinal detachment.
2.1 Non-Proliferative Diabetic Retinopathy (NPDR)
2.1.1 Mild NPDR
Characterized by the presence of at least one retinal microaneurysm. This stage is often asymptomatic and may regress with improved metabolic control.
2.1.2 Moderate NPDR
Features include multiple microaneurysms, dot-and-blot hemorrhages, hard exudates, and cotton-wool spots. The extent of capillary nonperfusion remains limited.
2.1.3 Severe NPDR
Defined by the “4-2-1 rule”: hemorrhages and microaneurysms in four quadrants, venous beading in two or more quadrants, or intraretinal microvascular abnormalities (IRMA) in at least one quadrant. High risk of progression to proliferative disease.
2.2 Proliferative Diabetic Retinopathy (PDR)
2.2.1 Early PDR
Characterized by neovascularization elsewhere (NVE) on the retina or neovascularization of the optic disc (NVD) not yet meeting high-risk criteria. Vitreous hemorrhage may occur.
2.2.2 High-Risk PDR
Defined by the Diabetic Retinopathy Study as the presence of any three of four features: NVD, vitreous hemorrhage, NVE > one-half disc area, or preretinal hemorrhage. Immediate treatment is indicated to prevent severe vision loss.
2.3 Diabetic Macular Edema (DME)
2.3.1 Center-Involving DME
Edema affecting the foveal center, detected on optical coherence tomography (OCT) as retinal thickening within 1 mm of the fovea. This subtype is the most common cause of vision loss in diabetic retinopathy.
2.3.2 Non-Center-Involving DME
Edema located outside the foveal center, often detected as retinal thickening in the posterior pole but sparing the fovea. Visual acuity may remain normal until progression.
3.1 Symptoms
3.1.1 Asymptomatic Early Stages
Mild and moderate NPDR typically produce no visual symptoms. Patients may be unaware of retinal changes until advanced disease.
3.1.2 Floaters, Blurred Vision, and Visual Field Defects
Vitreous hemorrhage causes sudden floaters, cobwebs, or dark spots. Macular edema leads to central blurring and metamorphopsia. Tractional detachment or extensive ischemia may produce scotomas or visual field loss.
3.2 Diagnostic Methods
3.2.1 Dilated Fundus Examination
Stereoscopic slit-lamp biomicroscopy through a dilated pupil allows direct visualization of microaneurysms, hemorrhages, exudates, cotton-wool spots, venous beading, and neovascularization. It remains the first-line screening tool.
3.2.2 Fluorescein Angiography
Intravenous injection of sodium fluorescein captures retinal and choroidal circulation. It highlights areas of capillary nonperfusion, microaneurysm leakage, neovascularization, and macular edema. Late-phase images delineate leakage zones.
3.2.3 Optical Coherence Tomography (OCT)
Cross-sectional imaging of retinal layers provides quantitative measurement of macular thickness, cystoid spaces, and subretinal fluid. OCT is essential for diagnosing and monitoring diabetic macular edema.
3.2.4 OCT Angiography
A noninvasive technique that generates depth-resolved maps of retinal and choroidal vasculature without dye injection. It visualizes capillary dropout, microaneurysms, and neovascular complexes, offering complementary information to fluorescein angiography.
4.1 Modifiable Risk Factors
4.1.1 Glycemic Control (HbA1c Targets)
Tight glycemic control (HbA1c < 7%) reduces the incidence and progression of diabetic retinopathy, as demonstrated by the Diabetes Control and Complications Trial (DCCT) for type 1 diabetes and the United Kingdom Prospective Diabetes Study (UKPDS) for type 2 diabetes.
4.1.2 Blood Pressure and Lipid Management
Systolic blood pressure targets < 130 mmHg and lipid-lowering therapy (e.g., statins) decrease the risk of retinal hard exudates and macular edema. The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study showed fenofibrate reduced retinopathy progression.
4.1.3 Smoking Cessation
Smoking exacerbates vascular damage by promoting oxidative stress and endothelial dysfunction. Cessation reduces overall diabetic complication risk, including retinopathy.
4.2 Non-Modifiable Risk Factors
4.2.1 Duration of Diabetes
After 20 years of diabetes, nearly all patients with type 1 and >60% with type 2 develop some degree of retinopathy. Duration is the strongest predictor.
4.2.2 Genetic Predisposition
Twin studies and genome-wide association analyses have identified susceptibility loci (e.g., near VEGFA, ERG, and COL25A1). Genetic factors may influence interindividual variability in retinopathy risk.
5.1 Medical Management
5.1.1 Intensive Diabetes Control
Optimization of glucose, blood pressure, and lipids remains the foundation for preventing retinopathy onset and slowing progression. In patients with advanced disease, rapid intensive control may transiently worsen retinopathy (e.g., early worsening phenomenon) and is monitored carefully.
5.1.2 Anti-VEGF Intravitreal Injections
Monoclonal antibodies such as ranibizumab (Lucentis), aflibercept (Eylea), off-label bevacizumab (Avastin), and newer agents like faricimab (Vabysmo) inhibit VEGF. They are first-line therapy for center-involving DME and are effective for treating PDR with or without DME. Typical regimens involve monthly or treat-and-extend dosing.
5.1.3 Corticosteroid Implants
Dexamethasone (Ozurdex) and fluocinolone acetonide (Iluvien) implants reduce edema by suppressing inflammation and lowering VEGF indirectly. They are reserved for patients with persistent DME despite anti-VEGF therapy or in pseudophakic eyes, as they accelerate cataract formation and raise intraocular pressure.
5.2 Laser Photocoagulation
5.2.1 Panretinal Photocoagulation for PDR
Application of 1,200–1,600 laser burns to the peripheral retina reduces total retinal oxygen demand and induces regression of neovascularization. This procedure was the historical standard for PDR but is now often deferred in favor of anti-VEGF, except in cases with poor compliance or extensive neovascularization.
5.2.2 Focal/Grid Laser for DME
Laser burns applied to leaking microaneurysms (focal) or in a grid pattern over edematous areas (grid) reduce edema. This technique is less commonly used as primary therapy since the advent of anti-VEGF injections, but it remains an option for non-center-involving DME or in combination with injections.
5.3 Surgical Interventions
5.3.1 Vitrectomy for Vitreous Hemorrhage
Pars plana vitrectomy removes vitreous hemorrhage and clears the visual axis. It is indicated when hemorrhage fails to clear spontaneously within 3–6 months, or earlier in type 1 diabetes or bilateral disease. Additional laser or anti-VEGF may be performed concurrently.
5.3.2 Retinal Repair for Tractional Detachment
In the presence of tractional retinal detachment involving the macula, vitrectomy with membrane peeling is performed to relieve traction and reattach the retina. Silicone oil tamponade may be used if adequate gas tamponade is not possible. Surgery is also considered for progressive fibrovascular proliferation or combined tractional-rhegmatogenous detachment.
6.1 Visual Outcomes with Early Treatment
With timely diagnosis and intervention (e.g., anti-VEGF, laser), many patients maintain functional vision. Clinical trials (e.g., DRCR.net Protocol S) have shown that anti-VEGF therapy for PDR can achieve non-inferior visual outcomes to panretinal photocoagulation while offering less visual field loss.
6.2 Long-Term Risks
6.2.1 Vitreous Hemorrhage Recurrence
Even after successful regression of neovascularization, residual fibrovascular fronds can bleed. Recurrent hemorrhage may require repeated anti-VEGF or vitrectomy. The cumulative incidence of recurrent vitreous hemorrhage after initial vitrectomy ranges from 10% to 30%.
6.2.2 Neovascular Glaucoma
Prolonged retinal ischemia leads to iris and angle neovascularization (rubeosis iridis), blocking the aqueous drainage pathway and causing neovascular glaucoma. This is a devastating complication characterized by elevated intraocular pressure, pain, and rapid vision loss. Treatment includes anti-VEGF injections, panretinal photocoagulation, and glaucoma surgery.
6.2.3 Tractional Retinal Detachment
Fibrovascular proliferation contracts and pulls the retina away from the retinal pigment epithelium. If the macula detaches, surgical repair is urgent to prevent permanent vision loss. Even with successful reattachment, photoreceptor damage may limit visual recovery.
7.1 Emerging Pharmacotherapies
Novel agents targeting alternative pathways are under investigation, including Tie2 activators (e.g., faricimab, which also inhibits Ang-2), integrin antagonists, and neuroprotective drugs. Oral medications (e.g., fenofibrate, methylglyoxal scavengers, protein kinase C inhibitors) are being evaluated for early-stage disease prevention.
7.2 Artificial Intelligence in Screening
Deep learning algorithms applied to retinal photographs can detect diabetic retinopathy with accuracy comparable to human specialists. The U.S. Food and Drug Administration has approved autonomous AI systems for screening in primary care settings, increasing access in underserved populations. Challenges remain in validating AI across diverse ethnic groups and imaging devices.
7.3 Genetic and Biomarker Studies
Large-scale genome-wide association studies continue to identify novel susceptibility loci. Epigenetic modifications (e.g., DNA methylation at promoter regions of genes related to inflammation and angiogenesis) are being examined as potential biomarkers for disease progression. Proteomic and metabolomic profiling of vitreous and serum may enable risk stratification and personalized therapeutic strategies.